Sign in

    John Houston

    President and Chief Executive Officer at Arvinas Inc
    Board
    Since September 2017
    Age
    65 years
    Education
    Holds a Ph.D. in microbial biochemistry from Heriot-Watt University, Edinburgh, and a B.Sc. in medical microbiology from the University of Glasgow.
    Tenure
    Joined ARVN in September 2017 as President and Chief Executive Officer, serving in additional roles such as President of Research and Development, Chief Scientific Officer, and Principal Executive Officer, and was promoted to Chairperson in June 2023.

    Also at Arvinas Inc

    AS
    Andrew Saik
    Chief Financial Officer, Treasurer, and Principal Financial Officer
    AC
    Angela Cacace
    Chief Scientific Officer
    IT
    Ian Taylor
    President of Research and Development

    About

    John Houston, Ph.D., has a robust academic foundation with advanced degrees in microbial biochemistry and medical microbiology, which have equipped him with deep scientific expertise.

    With extensive experience in the pharmaceutical and biotechnology sectors, he held senior roles at organizations including Bristol-Myers Squibb and Glaxo Wellcome Research and Development, contributing to innovative research and discovery.

    At ARVN, he has played a pivotal leadership role since September 2017 as President and Chief Executive Officer, undertaking additional responsibilities as President of Research and Development, Chief Scientific Officer, and Principal Executive Officer, and later being promoted to Chairperson in June 2023.

    $ARVN Performance Under John Houston

    Past Roles

    OrganizationRoleDate RangeDetails
    Arvinas (ARVN) President of Research and Development January 2017 - June 2024 Former role prior to CEO appointment
    Arvinas (ARVN) Chief Scientific Officer January 2017 - April 2019 Former role
    Arvinas (ARVN) Principal Executive Officer Since February 2017 Former role
    Bristol-Myers Squibb Senior Vice President, Head of Specialty Discovery September 2015 - August 2016 Former role
    Bristol-Myers Squibb Senior Vice President of Disease Sciences, Biologics and Applied Biotechnology August 2008 - September 2015 Former role
    Glaxo Wellcome R&D (UK) Head of the Lead Discovery Unit N/A Former role

    Fixed Compensation

    Data from  FY 2024
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary $684,0052024 (annual)Guaranteed base salary for 2024
    401(k) Matching Contributions $13,8002024 (as earned)401(k) match provided during 2024
    Stock Awards (RSUs) $11,622,357 (grant fair value)<br>124,450 RSUsGrant Date: February 23, 2024Grant Date Stock Price: $47.00 per share; Vesting details not explicitly provided
    Option Awards 184,200 optionsGrant Date: February 23, 2024;<br>50% vest on February 23, 2025, 50% vest on February 23, 2026Exercise Price: $47.00 per share; Grant Date Fair Value: $11,622,357

    Performance Compensation

    Data from  FY 2024

    Non-Equity Incentive Plan Compensation

    MetricValueAdditional Details
    Bonus Target Percentage 60% of base salaryBonus tied solely to achievement of corporate goals; no thresholds or caps specified
    Actual Payout Amount $426,819Earned in 2024 and paid in 2025
    Payment Timing Earned in 2024, paid in 2025Cash-based bonus program without vesting requirements
    Performance Conditions Achievement of corporate goalsNo additional performance metrics, thresholds, caps, or weighted targets provided